NCT05409664 (MFT4) is a NA clinical trial of Physical activity adoption in Breast Cancer, sponsored by University of South Carolina.

Who is sponsoring NCT05409664?

NCT05409664 is sponsored by University of South Carolina.

What drugs are being tested in NCT05409664?

Interventions in NCT05409664: Physical activity adoption, Self monitoring.

What condition does NCT05409664 study?

NCT05409664 studies Breast Cancer, Physical Inactivity.

Is NCT05409664 still recruiting?

NCT05409664 is currently active, enrolled. Last updated 15 May 2025.

Last reviewed 2025-05-15 · How we verify

NCT05409664: MFT4

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Moving Forward Together 4

Active, enrolled NA Last updated 15 May 2025

What this trial tests

NA trial testing Physical activity adoption in Breast Cancer in 68 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

10 November 2022

Primary endpoint
1 May 2025

31 January 2026

Quick facts

Lead sponsor	University of South Carolina
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	supportive care
Enrollment	68
Start date	10 November 2022
Primary completion	1 May 2025
Estimated completion	31 January 2026
Sites	1 location across United States

Drugs / interventions tested

Physical activity adoption
Self monitoring

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
Physical Inactivity — all drugs for Physical Inactivity →

Sponsor

University of South Carolina

Who can join

21 and older, female only, with Breast Cancer or Physical Inactivity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a 3-month physical activity intervention aimed to increase moderate-intensity activity among previously inactive breast cancer survivors. Participants will be eligible if they are not currently active, and have recently been diagnosed with breast cancer. Upon eligibility, participants will be randomized into one of two groups. The intervention group will receive weekly guidance from a peer coach to increase their activity throughout the three month intervention. The control group will be encouraged to self-monitor their physical activity throughout the three month intervention. Both groups will receive a Fitbit. Peer coaches will be trained to deliver the physical activity program using a web-based platform; all calls will be virtual. Participants will be assessed before and after the intervention.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Effects of web platform delivery of a physical activity program for breast cancer survivors: a randomized controlled trial.
Pinto BM, Kindred M, Dunsiger S, Mitchell S, et al · · 2025 · cited 2× · PMID 40423894 · DOI 10.1007/s11764-025-01811-7
Adapting an Efficacious Peer-Delivered Physical Activity Program for Survivors of Breast Cancer for Web Platform Delivery: Protocol for a 2-Phase Study.
Pinto BM, Patel A, Ostendorf DM, Huebschmann AG, et al · · 2024 · cited 2× · PMID 38896452 · DOI 10.2196/52494
Adopting and implementing an efficacious peer-delivered physical activity program for web platform delivery in survivors of breast cancer: organizational readiness and perspectives.
Ostendorf DM, Huebschmann AG, Wickersham KE, Kindred M, et al · · 2025 · PMID 41005365 · DOI 10.1093/tbm/ibaf051

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other University of South Carolina trials

Trials by the same sponsor.

NCT06469749 — Theory-based Social Media Intervention for Non-medical Use of Prescription Opioids in Young Adults · NA · not yet recruiting
NCT07340580 — Implementation Facilitation of Exercise is Medicine Greenville · NA · not yet recruiting
NCT07518407 — Dietary Insights and Nutritional Education in Adults on GLP-1 Therapy · NA · not yet recruiting
NCT07340099 — Church Implementation of a Social Support Intervention to Increase Physical Activity in Older African American Adults · NA · not yet recruiting
NCT06024317 — Leveraging Community Health Workers and a Digital Health System to Improve the Timeliness of Child Well Visits · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05409664 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of South Carolina
Last refreshed: 15 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05409664.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing